Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Quanterix Corporation

< Previous 1 2 3 Next >
Quanterix Expands Reach with IVD and Large Reference Labs
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix to Present at Goldman Sachs Global Healthcare Conference
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Releases Financial Results for the First Quarter of 2025
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix and Akoya Biosciences Announce Amended Merger Agreement
From Quanterix Corporation
Via Business Wire
Tickers AKYA QTRX
Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Releases Financial Results for the Fourth Quarter of 2024
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix To Report Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Provides Update on Financial Performance
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers
From Quanterix Corporation
Via Business Wire
Tickers AKYA QTRX
David R. Walt Receives National Medal of Technology and Innovation
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Expands Capabilities with Strategic Acquisition of EMISSION
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Announces Receipt of Expected Notice from Nasdaq
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix To Report Third Quarter 2024 Financial Results on November 12, 2024
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Announces Commercialization of p-Tau 217 Test Kit
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix to Participate at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Jeffrey Elliott Appointed to Quanterix’s Board of Directors
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Releases Financial Results for the Second Quarter of 2024
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Presenting at Canaccord Genuity 44th Annual Growth Conference
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix To Report Second Quarter 2024 Financial Results
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Presents Data Demonstrating Successful Multi-Marker Approach for Alzheimer’s Disease Detection that is More Effective than Standalone Plasma p-Tau 217
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix to Participate at the Scotiabank Healthcare 1x1 Day
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix to Present at Leerink Partners Healthcare Crossroads Conference 2024
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Releases Financial Results for the First Quarter of 2024
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix To Report First Quarter 2024 Financial Results
From Quanterix Corporation
Via Business Wire
Tickers QTRX
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
From Quanterix Corporation
Via Business Wire
Tickers QTRX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.